Use of magnesium hydroxide in preparation of drug for treating arthralgia

By using nano or micron-level magnesium hydroxide particles as drug components, the problem of insignificant safety and efficacy of osteoarthritis treatment drugs in the prior art has been solved, and long-term joint pain relief and synovial inflammation have been achieved, which has significantly improved the risk of joint pain and improved synovial inflammation. Improved patient compliance.

WO2024230405A1PCT designated stage expired Publication Date: 2024-11-14XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/087380
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-05
Filing Date
2024-04-12
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing drugs for treating osteoarthritis pain have problems with insignificant safety and efficacy, especially after long-term use, which may cause cardiovascular and gastrointestinal side effects, and there is a lack of effective long-term analgesic plans.

Method used

Nano or micron-scale magnesium hydroxide particles are used as the active ingredient to prepare drugs for the treatment of joint pain through joint cavity injection, and combined with acceptable carriers or additives to form injection preparations to improve efficacy and safety.

Benefits of technology

Magnesium hydroxide significantly effectively and lastingly relieves joint pain in rats, reduces the frequency of administration, improves patient compliance, and significantly improves the status of synovitis and cartilage injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024087380_14112024_PF_FP_ABST
    Figure CN2024087380_14112024_PF_FP_ABST
Patent Text Reader

Abstract

A use of magnesium hydroxide in preparation of a drug for treating arthralgia. Rat tests prove that treatment with nanometer- or micron-sized magnesium hydroxide can effectively and durably relieve the arthralgia of OA rats, that is, magnesium hydroxide can be used for preparing a drug for treating arthralgia. The drug can significantly reduce the frequency of administration, thereby improving the compliance of patients.
Need to check novelty before this filing date? Find Prior Art

Description

Application of magnesium hydroxide in preparing medicine for treating joint pain

[0001] This application claims priority to the Chinese patent application filed with the State Intellectual Property Office of China on May 5, 2023, with application number 202310496323.3 and invention patent name “Magnesium hydroxide nanoparticles for treating joint pain, preparation method and application thereof”, the entire contents of which are incorporated by reference into this application.

[0002] This application claims priority to the Chinese patent application filed with the State Intellectual Property Office of China on May 5, 2023, with application number 202310497579.6 and invention patent name “Application of magnesium hydroxide in the preparation of drugs for treating joint pain”, the entire contents of which are incorporated by reference into this application. Technical Field

[0003] The invention belongs to the field of medicine, and particularly relates to application of magnesium hydroxide in preparing medicine for treating joint pain. Background Art

[0004] Osteoarthritis (OA) is a degenerative disease characterized by joint pain, often affecting the knees, hips, spine, and hands, resulting from fibrosis, cracking, ulceration, and loss of articular cartilage caused by multiple factors. Its pathological features include degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic changes, bone hyperplasia at the joint margins, and synovitis. OA severely impacts joint function and quality of life, and studies have shown that OA, particularly symptomatic knee OA, can significantly increase all-cause mortality. Unfortunately, there are currently no safe and effective treatments available to slow the progression of OA, both domestically and internationally.

[0005] Joint pain is the most common clinical manifestation of osteoarthritis (OA), and analgesia is the primary medical concern for OA patients. As the disease progresses, OA patients often experience persistent pain, making long-term, safe analgesia crucial for OA patients. Currently, treatments for OA patients primarily focus on joint analgesia, and while these treatments are numerous, they present numerous challenges. For example, acetaminophen has historically been a first-line treatment for OA pain, but recent high-quality research evidence shows that it is not only ineffective in relieving OA pain compared to placebo but also significantly increases the risk of gastrointestinal side effects. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are clearly effective in relieving OA pain, but long-term use can cause cardiovascular and gastrointestinal side effects, raising concerns. Oral tramadol was recommended as a "first-line" treatment in both the 2013 American Academy of Orthopaedic Surgeons and the 2012 American College of Rheumatology OA guidelines, but recent studies have found that oral tramadol significantly increases all-cause mortality, myocardial infarction, and hip fracture rates compared to NSAIDs (this has been incorporated into the 2019 American College of Rheumatology OA guidelines, which no longer recommend tramadol as a "first-line" treatment). Intra-articular corticosteroid injections are widely used and have significant short-term analgesic effects, but they pose important challenges that need to be addressed, including a short-lived analgesic effect, a lack of significant efficacy, and safety concerns. Therefore, further exploration of effective and safe long-term OA analgesic treatments is urgently needed.

[0006] The main medical use of magnesium hydroxide is as an acid-reducing agent. Clinically, magnesium hydroxide is primarily used as a cathartic agent, often before colonoscopy and intestinal surgery, to promote the excretion of feces. However, there are currently no reports of its use as a long-term analgesic for OA.

[0007] Therefore, based on this, the technical solution of the present invention is proposed.

[0008] Summary of the Invention

[0009] To address the problems of the prior art, the present invention provides the use of magnesium hydroxide in the preparation of a medicament for treating joint pain. During research on the pharmacological effects of magnesium hydroxide, the inventors discovered that intra-articular injection of magnesium hydroxide has a good and long-lasting analgesic effect on OA.

[0010] The present invention provides an application of magnesium hydroxide in the preparation of a medicine for treating joint pain.

[0011] Application of magnesium hydroxide in preparing medicine for treating synovitis and cartilage damage.

[0012] Preferably, the magnesium hydroxide is used in the preparation of a drug having a long-lasting joint analgesic effect.

[0013] Preferably, the joint pain is osteoarthritis joint pain.

[0014] Preferably, the cartilage damage is cartilage damage caused by joint degeneration, inflammatory changes, various types of trauma, or chronic wear. Preferably, the magnesium hydroxide is nano-sized magnesium hydroxide particles.

[0015] Preferably, the magnesium hydroxide is micron-sized magnesium hydroxide particles.

[0016] Preferably, the average particle size of the magnesium hydroxide is 50 nm to 20 μm.

[0017] Preferably, the drug is an injectable preparation.

[0018] Preferably, the drug is used for intra-articular injection.

[0019] Preferably, the drug is a preparation prepared with magnesium hydroxide as the main drug and a medically acceptable carrier or additive.

[0020] Preferably, the carrier or additive is selected from one or a combination of solvents, osmotic pressure regulators, pH regulators, stabilizers, suspending agents, surfactants or preservatives.

[0021] The beneficial effects of the present invention are:

[0022] Experiments on rats have shown that nano- or micron-sized magnesium hydroxide treatment can effectively and durably relieve the joint pain of OA rats. That is, magnesium hydroxide can be used to prepare drugs for treating joint analgesia, which will greatly reduce the frequency of administration and thus improve patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0024] FIG1 is a graph showing the mechanical paw withdrawal threshold results of rats in each group.

[0025] FIG2 is a data diagram showing the difference in bipedal weight bearing results of rats in each group.

[0026] FIG3 is HE staining of the knee joints of rats in each group. DETAILED DESCRIPTION

[0027] To make the objectives, technical solutions, and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other implementations obtained by those of ordinary skill in the art without inventive effort are within the scope of protection of the present invention.

[0028] Example 1: Pharmacodynamics test

[0029] An OA rat model was established by intra-articular injection of sodium iodoacetate into the knee joints of SD rats. The OA rat model was established when the rats' knee joints swelled and their pain threshold significantly decreased. Seven days after modeling, the OA rats were treated with equal volumes (100 μL) of normal saline, magnesium sulfate solution at a concentration of 0.35 mmol / mL (calculated as magnesium), magnesium hydroxide nanosolution, and magnesium hydroxide suspension via intra-articular injection. These rats were designated as the normal saline group, magnesium sulfate solution group, nanomagnesium hydroxide group, and micromagnesium hydroxide group, respectively.

[0030] The preparation method of the magnesium sulfate solution is as follows: dissolving magnesium sulfate heptahydrate in physiological saline.

[0031] The preparation method of magnesium hydroxide nano-liquid is as follows: suspend nano-magnesium hydroxide (Aladdin, 99.8%) in normal saline (the average particle size of nano-magnesium hydroxide is 55nm).

[0032] The preparation method of magnesium hydroxide suspension is as follows: magnesium hydroxide raw material (Puli Pharmaceutical) is processed by air flow mill and then suspended in normal saline (the average particle size of micron-sized magnesium hydroxide is 19.2 μm).

[0033] In addition, an equal volume of normal saline was injected into the knee joint cavity of normal rats as a control (denoted as the normal group).

[0034] The drug was administered once. Starting from the first day of administration, the mechanical paw withdrawal threshold and the difference in weight bearing between the two paws of the rats in each group were measured once a week. The results are shown in Figures 1 and 2.

[0035] As shown in Figures 1 and 2, magnesium sulfate can alleviate joint pain in OA rats to a certain extent, but the duration is short. However, nano- or micro-sized magnesium hydroxide treatment can effectively and persistently alleviate joint pain in OA rats. These results fully demonstrate that the magnesium hydroxide of the present invention can be used to prepare a drug for treating joint pain.

[0036] Example 2: Pharmacodynamics test

[0037] An OA rat model was established by intra-articular injection of sodium iodoacetate into the knee joints of SD rats. The OA rat model was established when the knee joints swelled and the pain threshold significantly decreased. Seven days after modeling, the OA rats were treated with normal saline, 0.35 mmol / mL (calculated as magnesium) magnesium sulfate solution, magnesium hydroxide nanosolution, and magnesium hydroxide suspension via intra-articular injection. These treatments were designated as the normal saline group, magnesium sulfate solution group, nanomagnesium hydroxide group, and micromagnesium hydroxide group, respectively.

[0038] The preparation method of the magnesium sulfate solution is as follows: dissolving magnesium sulfate heptahydrate in physiological saline.

[0039] The preparation method of magnesium hydroxide nano-liquid is as follows: suspending nano-magnesium hydroxide (Aladdin, 99.8%) in physiological saline.

[0040] The preparation method of the magnesium hydroxide suspension is as follows: the magnesium hydroxide raw material (Puli Pharmaceutical) is processed by a jet mill and then suspended in physiological saline.

[0041] In addition, an equal volume of normal saline was injected into the knee joint cavity of normal rats as a control (denoted as the normal group).

[0042] The drug was administered once. Four weeks after administration, paraffin sections of the treated knee joints were taken and stained with hematoxylin and eosin (HE). The results are shown in Figure 3. The results showed that the saline group had significant synovial inflammation and severe cartilage destruction. After treatment with magnesium sulfate solution, the synovitis and cartilage damage in OA rats were alleviated to a certain extent. In contrast, synovial inflammation in OA rats treated with nano- and micro-magnesium hydroxide was greatly improved, and cartilage damage was also effectively suppressed, with the condition approaching that of normal rats. These results indicate that magnesium hydroxide can effectively inhibit synovitis and cartilage destruction.

[0043] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in the present invention should be included in the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection of the claims.

Claims

1. The application of magnesium hydroxide in the preparation of medicines for treating joint pain.

2. The application of magnesium hydroxide in the preparation of medicines for treating synovitis and cartilage damage.

3. The use according to claim 1, characterized in that: The magnesium hydroxide is used in preparing a medicine with a long-acting joint analgesic effect.

4. The use according to claim 1 or 3, characterized in that: The joint pain is joint pain caused by osteoarthritis.

5. The use according to claim 2, characterized in that: The cartilage damage is cartilage damage caused by joint degeneration, inflammatory changes, various types of trauma or chronic wear.

6. The use according to claim 1 or 2, characterized in that: The magnesium hydroxide is nano-sized magnesium hydroxide particles.

7. The use according to claim 1 or 2, characterized in that: The magnesium hydroxide is micron-sized magnesium hydroxide particles.

8. The use according to claim 6 or 7, characterized in that: The average particle size of the magnesium hydroxide is 50 nm to 20 μm.

9. The use according to claim 1 or 2, characterized in that: The medicine is an injection preparation.

10. The use according to claim 9, characterized in that: The medicine is used for intra-articular injection.

11. The use according to claim 10, characterized in that: The medicine is a preparation prepared by taking magnesium hydroxide as a main drug and adding a medically acceptable carrier or additive.

12. The use according to claim 11, characterized in that: The carrier or additive is selected from one or a combination of solvents, osmotic pressure regulators, pH regulators, stabilizers, suspending agents, surfactants or preservatives.

Citation Information

Patent Citations

  • Application of magnesium hydroxide in preparing medicine for treating joint pain

    CN117562920B

  • Formulations and methods for delaying onset of chronic neuropathic pain

    CN104427987A

  • Magnesium hyaluronate for treating osteoarthritis and preparation method and application thereof

    CN107840897A

  • Application of compound combination in preparation of injection for treating osteoarthritis

    CN113244259A

  • Magnesium hydroxide nanoparticles for treating arthralgia as well as preparation method and application of magnesium hydroxide nanoparticles

    CN117562869A